Navigation Links
Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
Date:2/25/2011

d to 12 months for those with high expression.

AEG-1 is a cancer-associated gene with multiple functions, which contribute to several hallmarks of cancer including drug-resistance.

Perhaps the greatest potential for AEG-1 expression would be to couple it with measurements of the expression of the BRCA1 gene, Dr Rosell said.

"Combining these two measurements could have very important clinical implications since defining a low-risk subgroup of patients can accurately predict situations when the simple administration of an oral EGFR drug could have an extremely durable effect, of more than two years."

"This could give confidence to the patient, their family and doctors, and eliminate the traditional anxiety of waiting for periodical CT scan reassessments," Dr Rosell said. "While radiographic monitoring will not be left to one side altogether, the patient and family can face these tests without anxiety."

For those patients in the high-risk group, the result can alert the clinical oncologist to be ready for early progression and look for alternative management strategy, Dr Rosell said.

Commenting on the research, which she was not involved in, Dr Fiona Blackhall, Consultant Medical Oncologist and Honorary Senior Lecturer at The Christie Hospital NHS Foundation Trust and Manchester Cancer Research Centre, UK, explained that Dr Rosell and colleagues applied innovative nanostring technology to address why, despite presence of EGFR gene mutation, clinical outcomes with erlotinib treatment (response rate and duration of response) are heterogeneous.

"They have discovered that AEG-1, a gene that activates several molecular pathways implicated in drug resistance, is a strong predictor of progression-free survival in the context of EGFR gene mutation and erlotinib treatment. This finding provides new insight into molecular mechanisms driving resistance to EGFR-tyrosine kinase inhibitors that may be exploited for t
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Fox Chase researchers uncover one force behind the MYC oncogene in many cancers
2. Doctors not strongly encouraging HPV vaccine to girls of certain age
3. New model predicts hot spots for mercury in fish
4. Pregnancy hormone predicts postpartum depression
5. Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer
6. Study predicts when invasive species can travel more readily by air
7. Blood test predicts chance of dementia
8. Computer model predicts brain tumor growth and evolution
9. NOAA forecast predicts large dead zone for Gulf of Mexico this summer
10. Gene predicts how brain responds to fatigue, human study shows
11. Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... HOUSTON (Aug. 20, 2008) The genetic code of a ... of genes function in humans and other species. A study ... the genetic code of Trichoplax , a simple saltwater creature ... common household aquarium. "We,re trying to identify, in the ...
... biodegradable polymers called polyketals and their derivatives may improve ... acute liver failure and inflammatory bowel disease by delivering ... locations in the body. "The polyketal microparticles we ... inside the body to the diseased area as quickly ...
... Researchers here have found a way to convert ethanol ... new catalyst makes hydrogen from ethanol with 90 percent ... Umit Ozkan, professor of chemical and biomolecular engineering ... is much less expensive than others being developed around ...
Cached Biology News:Genome of saltwater creature could aid understanding of gene grouping 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 3A better way to make hydrogen from biofuels 2A better way to make hydrogen from biofuels 3
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available ... NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for extreme ... are able to enter fat cells, inhibiting the formation of new fat. Upon ...
(Date:7/28/2015)... A n ew UK company ... commercialising innovative medicines to transform patient quality of life and ... team; blue chip investor ... Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that it ... blue chip institutional investors and simultaneously acquired a portfolio of ...
(Date:7/28/2015)... July 28, 2015 Seahorse Bioscience, the ... is the provider of XF Technology which is ... research areas. As the links between mitochondrial function ... metabolism is escalating rapidly.   Recently, ... Nature Publishing Group (NPG) featuring XF Technology, including ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... Inc. (NYSE: BMR ) today announced it will ... after the market closes on Wednesday, November 3, 2010. ... Kent Griffin, President, and Greg N. Lubushkin, Chief Financial Officer, ... Time on Thursday, November 4, 2010 to discuss the company,s ...
... announced a partnership to advance the use of biofuels by ... effort involves entrepreneurs John Fox ,92 and Wayne Arden, who ... achieve multiple benefits, including reducing risks to American troops and ... With energy demands growing at home bases along with ...
... Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com ) announced ... to the Company and a member of the Company,s ... of the reverse stock split proposal being considered at ... "Having been intimately involved in the drug development world ...
Cached Biology Technology:BioMed Realty Trust to Report 2010 Third Quarter Results 2Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 2Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 3Syracuse University Partners with Arden-Fox to Support the Advancement of Department of Defense's Net Zero Energy Initiative 4Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 2Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 3Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders 4
... is an enhanced form of Tobacco Etch ... highly active, and significantly more stable than ... AcTEV Protease specifically recognizes a seven amino ... making it useful for removing affinity tags ...
versican (H-56)...
Vapor phase risers are available in various heights to accomodate a variety of inventory solutions. Risers are used to creat a false bottom in which the tanks platform rests and Liquid nitrogen is s...
... Anti-M13 polyclonal antibody was derived from ... phage particles.Recombinant protein domains such as antibody ... protein pIII and displayed on phage using ... system utilized in the Ph.D. libraries. Anti-M13 ...
Biology Products: